Ketan Dhatariya
Overview
Explore the profile of Ketan Dhatariya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
1410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Avari P, Choudhary P, Lumb A, Misra S, Rayman G, Flanagan D, et al.
Diabet Med
. 2024 Oct;
42(3):e15452.
PMID: 39432570
This article summarises the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group guidelines on the use of technology to support diabetes care in hospital. The guideline incorporates two main...
12.
Dasgupta I, Zac-Varghese S, Chaudhry K, McCafferty K, Winocour P, Chowdhury T, et al.
Diabet Med
. 2024 Oct;
42(2):e15450.
PMID: 39415639
A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes-related CKD is a leading cause of end-stage kidney disease (ESKD) and people with diabetes and...
13.
Limbachia V, Nunney I, Page D, Barton H, Patel L, Thomason G, et al.
Clin Med (Lond)
. 2024 Oct;
24(6):100249.
PMID: 39368664
Background: Corticosteroids raise blood glucose concentrations; however, it remains unknown which form of administration, oral or intravenous, is associated with the greatest degree of blood glucose rise in hospitalised patients....
14.
Saravanan P, Bell H, Braae U, Collins E, Deinega A, Dhatariya K, et al.
Adv Ther
. 2024 Sep;
41(11):4266-4281.
PMID: 39316289
Introduction: Oral semaglutide provides an alternative to injectable glucagon-like peptide-1 receptor agonists (GLP-1RAs) for treatment of type 2 diabetes (T2D). The PIONEER REAL studies evaluate clinical outcomes of oral semaglutide...
15.
Staniszewska A, Game F, Nixon J, Russell D, Armstrong D, Ashmore C, et al.
Diabetes Care
. 2024 Sep;
47(11):1958-1968.
PMID: 39240785
Objective: Diabetes affects 537 million people globally, with 34% expected to develop foot ulceration in their lifetime. Diabetes-related foot ulceration causes strain on health care systems worldwide, necessitating provision of...
16.
Thomason G, Gooday C, Nunney I, Dhatariya K
Diabetes Ther
. 2024 Aug;
15(10):2223-2232.
PMID: 39153153
Introduction: This study aimed to determine the relationship between HbA variability and foot ulcer healing at 12 weeks and 12 months. Methods: Using National Diabetic Foot Care Audit (NDFA) and...
17.
Zac-Varghese S, Mark P, Bain S, Banerjee D, Chowdhury T, Dasgupta I, et al.
BMC Nephrol
. 2024 Jul;
25(1):216.
PMID: 38971750
The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk...
18.
Prothero L, Strudwick T, Foster T, Lake A, Boyle A, Clark A, et al.
Diabet Med
. 2024 Jun;
41(9):e15372.
PMID: 38853420
Aim: To determine whether it was feasible, safe and acceptable for ambulance clinicians to use capillary blood ketone meters for 'high-risk' diabetic ketoacidosis (DKA) recognition and fluid initiation, to inform...
19.
Farndon D, Bennett P, Nunney I, Dhatariya K
Ann Vasc Surg
. 2024 Apr;
105:132-139.
PMID: 38588955
Background: Glycemic variability (GV), measured as the change in visit-to-visit glycated hemoglobin (HbA), increases the risk of multiple adverse outcomes. However, the impact of GV on graft patency following infrainguinal...
20.
Valabhji J, Holman N, Collins N, Young R, Chadwick P, Robinson A, et al.
Diabetologia
. 2024 Apr;
67(7):1304-1314.
PMID: 38584181
Aims/hypothesis: The risk of dying within 2 years of presentation with diabetic foot ulceration is over six times the risk of amputation, with CVD the major contributor. Using an observational...